Arnie Pye
Senior Member (Voting Rights)
Title : ‘Disruptive’ science has declined — and no one knows why
Subtitle : The proportion of publications that send a field in a new direction has plummeted over the past half-century.
Link : https://www.nature.com/articles/d41586-022-04577-5
Posted : 4th January 2023
1) My assumption would be that Eminence Based Medicine creates a dam preventing anything disruptive from getting any exposure.
2) The pharma companies don't want anything to come along that might cure people.
3) Then of course, there is the "problem", related to 2 above, that Goldman Sachs highlighted :
Article Title : “Is curing patients a sustainable business model?” Goldman Sachs analysts ask
Link : https://arstechnica.com/tech-policy...le-business-model-goldman-sachs-analysts-say/
Subtitle : The proportion of publications that send a field in a new direction has plummeted over the past half-century.
Link : https://www.nature.com/articles/d41586-022-04577-5
Posted : 4th January 2023
The number of science and technology research papers published has skyrocketed over the past few decades — but the ‘disruptiveness’ of those papers has dropped, according to an analysis of how radically papers depart from the previous literature1.
Data from millions of manuscripts show that, compared with mid-twentieth-century research, that done in the 2000s was much more likely to push science forward incrementally than to veer off in a new direction and render previous work obsolete. Analysis of patents from 1976 to 2010 showed the same trend.
“The data suggest something is changing,” says Russell Funk, a sociologist at the University of Minnesota in Minneapolis and a co-author of the analysis, which was published on 4 January in Nature. “You don’t have quite the same intensity of breakthrough discoveries you once had.”
1) My assumption would be that Eminence Based Medicine creates a dam preventing anything disruptive from getting any exposure.
2) The pharma companies don't want anything to come along that might cure people.
3) Then of course, there is the "problem", related to 2 above, that Goldman Sachs highlighted :
Article Title : “Is curing patients a sustainable business model?” Goldman Sachs analysts ask
Link : https://arstechnica.com/tech-policy...le-business-model-goldman-sachs-analysts-say/